Sana Biotechnology, Inc. (SANA) News

Sana Biotechnology, Inc. (SANA): $7.77

0.26 (+3.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SANA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter SANA News Items

SANA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SANA News Highlights

  • SANA's 30 day story count now stands at 5.
  • Over the past 21 days, the trend for SANA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest SANA News From Around the Web

Below are the latest news stories about Sana Biotechnology Inc that investors may wish to consider to help them evaluate SANA as an investment opportunity.

Biotech IPOs Have Slowed to a Snail's Pace

Decline tied to falling stock prices of newly minted companies

Yahoo | February 17, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Sana Biotechnology: Exciting Preclinical Science

No summary available.

Seeking Alpha | February 12, 2022

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Yahoo | January 27, 2022

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications. IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products,

Yahoo | January 11, 2022

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes o

Yahoo | January 11, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA ), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, and Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today jointly announced that the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial ri...

Benzinga | January 10, 2022

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Tuesday, January 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of

Yahoo | January 4, 2022

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies

Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy

Yahoo | December 17, 2021

Sana Biotechnology (NASDAQ:SANA) Shares Gap Up to $17.65

Sana Biotechnology, Inc. (NASDAQ:SANA)s share price gapped up before the market opened on Monday . The stock had previously closed at $17.65, but opened at $18.99. Sana Biotechnology shares last traded at $18.34, with a volume of 2,080 shares traded. The company has a market capitalization of $3.16 billion and a PE ratio of -1.80. []

Transcript Daily | December 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4001 seconds.